Global Utilization And Registry Database for Improved heArt preservatioN

Condition(s) studied

Investigational drug(s) / intervention(s)

SherpaPak Cardiac Transport System: The Paragonix SherpaPak Cardiac Transport System ("SherpaPak CTS") is an ultraportable hypothermic preservation and transport system intended for use with donor hearts. The device is a legally marketed, FDA cleared medical device in the United States and CE Marked medical device in the European Union. The SherpaPak CTS consists of multiple components: 1) outer transport shipper which contains within various non-ice based temperature controlled packaging elements, 2) an inner and outer hard shell assembly which provides a rigid barrier enclosure in which the heart is immersed and suspended in a cold storage solution cleared for use in storing and transporting donor hearts, 3) a data logger that monitors and displays the temperature of the cold storage solution in which the heart is stored during transport, and 4) four size heart connectors designed to accommodate various size aortic stem diameters by which donor hearts are attached.

Study summary

The primary objective of this study is to collect real-world clinical performance data to assess the clinical outcomes of patients receiving heart transplants using donor hearts transported via the SherpaPak CTS System. These results will be compared to outcomes of retrospective patients whose hearts were transported with the previous standard method.

Eligibility

Primary outcome measure(s)

• Number of Patients with Primary Graft Dysfunction — one year
  Less than 40% LVEF by echocardiography or hemodynamics with RAP greater than 15 mm Hg, PCWP greater than 20 mm Hg, CI less thann 2 L/min/m\^2, hypotension with MAP less than 70 mm Hg (lasting more than 1 hour)
• Number of Patients with Right Ventricular Dysfunction — one year
  hemodynamics with RAP grater than 15mm Hg, PCWP less than 15 mm Hg, CI less than 2 L/min/m\^2, TPG less than 15mm Hg/pulmonary artery systolic pressure less than 50 mmHg OR need for RVAD
• Length of ICU Stay — one year
  Length of time patient admitted to the intensive care unit post transplant
• Length of Hospital Stay — one year
  Length of time before patient is discharged from the hospital post transplant
• Survival — 5 years
  The length of patient survival up to 5 years will be compared

Trial sites (22)

Other trials for the same condition